Washington, DC October 20, 2025 –(PR.com)– The National Coalition on Black Civic Participation (NCBCP) will host a historic celebration honoring Melanie L. Campbell’s 30 Years of Leadership and Service during the 28th Annual Spirit of Democracy Awards on Tuesday, October 21, 2025, from 6:00 p.m. – 9:30 p.m. at The Hamilton Live in Washington, D.C.
This year’s awards celebration marks a special milestone, recognizing President Campbell’s extraordinary three-decade of service and her journey as President and CEO of NCBCP and Convener of the Black Women’s Roundtable (BWR). Under her visionary leadership, NCBCP has become one of the nation’s most respected, Black-led civic engagement, social justice, and economic empowerment organizations. Under her leadership the organization has created several successful and nationally recognized programs to include Black Youth Vote (BYV), Black Women’s Roundtable, Unity Campaign, and NCBCP Thomas W. Dortch Jr. Institute at Clark Atlanta University.
Hosted by Karen Finney, TV Commentator, and Eugene Daniels, MSNBC Senior Washington Correspondent, co-host of MSNBC’s “The Weekend,” the evening will feature multiple special guests including Grammy-nominated artist Raheem DeVaughn, The Amours, and other.
“Melanie Campbell’s leadership has been a beacon of light in our fight for justice, equity, and democracy,” said Marc H. Morial, Chairman of the NCBCP Board of Directors and President & CEO of the National Urban League. “This celebration is not only about honoring her past achievements but also about reaffirming our commitment to the work ahead.”
The Spirit of Democracy Awards Gala, established nearly three decades ago, annually recognizes individuals and organizations whose work strengthens and uplifts Black communities through civic participation, leadership, and social change. This year, Melanie Campbell will be the sole honoree; an unprecedented acknowledgment of her tireless dedication to empowering Black women, youth, and families, and advancing racial, gender, and economic justice across America.
The celebration is made possible through the generous support of the NCBCP’s sponsors and partners, including the National Education Association (NEA), AARP, Gilead Sciences, SEIU, National Urban League, Amazon, Gender Justice Coalition and AFSCME.
Event Details:
What: 28th Annual Spirit of Democracy Awards – Celebrating Melanie L. Campbell’s 30 Years of Leadership & Service
When: Tuesday, October 21, 2025 | 6:00 p.m. – 9:30 p.m.
Where: The Hamilton Live | 600 14th St. NW, Washington, D.C. 20005
About the National Coalition on Black Civic Participation:
Founded in 1976, the National Coalition on Black Civic Participation (NCBCP) is a 501(c)(3) non-profit organization dedicated to increasing civic engagement, economic empowerment, and social justice in Black communities. Through its signature programs—the Black Women’s Roundtable (BWR), Black Youth Vote (BYV), and the Thomas W. Dortch, Jr. Institute for Leadership, Civic Engagement, Economic Empowerment & Social Justice—NCBCP works to build Black political, economic, and social power across generations.
Contact Information:
NCBCP
Tyrice Johnson
205-643-4755 Contact via Email
NCBCP.org
15-year exclusive license to deploy XCF’s modular, scalable renewable fuel platform across Australia, targeting development of three renewable fuel production facilities
XCF to receive a 12.5%equity stake, licensing fees, and one board seat in New Rise Australia
Formalizes the June 2025 Memorandum of Understanding and launches the first regional platform under XCF’s international expansion strategy
HOUSTON, TEXAS / ACCESS Newswire / October 23, 2025 / XCF Global, Inc. (“XCF”) (Nasdaq:SAFX), a key player in decarbonizing the aviation industry through Sustainable Aviation Fuel (“SAF”), today announces that it has signed a binding term sheet with New Rise Australia Pty. Ltd. (“New Rise AU”) to accelerate the development of renewable fuel production facilities across Australia.
The binding term sheet grants New Rise AU an exclusive 15-year license to use the design, layout, and configuration of XCF’s New Rise Reno facility to build and operate at least three SAF facilities across Australia. XCF will receive a 12.5% equity stake, licensing fees, and one board seat in New Rise AU.
Australia is emerging as one of the world’s most promising markets for renewable fuel. A Deloitte report commissioned by the Clean Energy Finance Corporation highlights a AUD$36 billion opportunity to develop a world-leading low-carbon liquid fuels (LCLF) industry capable of cutting emissions by 230 million tons by 2050 and strengthening the country’s energy independence.
Australia imports ~80% of its liquid fuels, spending more than AUD$50 billion in 2023 alone, while exporting AUD$3.9 billion in potential LCLF feedstocks. With less than 50 days of fuel reserves currently held onshore, well below the International Energy Agency’s recommended 90 days, the country’s reliance on imports leaves it vulnerable to global disruptions.
Recognizing this imbalance, the Australian federal government has prioritized low-carbon liquid fuels under its Future Made in Australia initiative, providing access to the AUD$1.7 billion Future Made in Australia Innovation Fund to support the development of a LCLF industry, which includes SAF and renewable diesel.
With major airlines like Qantas and Virgin Australia targeting net-zero emissions by 2050, demand for locally produced SAF is expected to surge, creating strong momentum for investment and development across the region.
This milestone builds on XCF’s international expansion strategy, built on capital-efficient, regionally tailored partnerships that accelerate global SAF adoption. It follows the June 2025 Memorandum of Understanding entered into with Continual Renewable Ventures Pty. Ltd., which laid the foundation for today’s binding agreement.
Mihir Dange, Chief Executive Officer of XCF Global, commented:
“Our partnership with New Rise AU accelerates XCF’s global expansion strategy and underscores the scalability of our modular renewable fuel platform. Australia combines strong policy momentum, growing aviation demand, and abundant feedstock resources, creating an excellent environment to develop renewable fuel facilities. Through New Rise AU, we’re deploying our renewable fuel platform to a new market, enabling rapid growth and efficient capital use while helping drive Australia’s clean energy transition. This partnership showcases how XCF’s platform transforms opportunity into impact, opening new markets, fueling sustainable growth, and shaping the future of renewable energy.”
Renzo Petersen, Chief Executive Officer of New Rise AU, added:
“The launch of New Rise Australia represents true collaboration between XCF Global and Continual Renewables, a partnership built on a shared vision to accelerate the decarbonization of the aviation industry. Together, we intend to create a unified platform that brings together XCF’s modular site design with Continual Renewable’s local expertise to unlock opportunities within Australia’s unique energy landscape. This is not simply a design deployment; it’s the foundation for a long-term, self-sustaining renewable fuel industry that drives investment, creates jobs, and accelerates Australia’s transition to energy independence. Together, we’re demonstrating how collaboration can be transformed into capability, and how capability becomes the clean energy that fuels Australia’s future.”
Building on today’s milestone, the parties intend to execute a definitive licensing agreement within 60 days, following customary diligence and regulatory review. The definitive agreement will include detailed provisions for intellectual property, branding, governance, performance milestones, and long-term operational coordination.
About XCF Global, Inc.
XCF Global, Inc. is a pioneering sustainable aviation fuel company dedicated to accelerating the aviation industry’s transition to net-zero emissions. XCF is developing and operating state-of-the-art clean fuel SAF production facilities engineered to the highest levels of compliance, reliability, and quality. The company is actively building partnerships across the energy and transportation sectors to accelerate the adoption of SAF on a global scale. XCF is listed on the Nasdaq Capital Market and trades under the ticker, SAFX. Current outstanding shares: ~159.2 million; <20% free float (as of October 23, 2025).
New Rise Australia Pty. Ltd. is an Australian-based company committed to building the infrastructure required to support the long-term decarbonization of the transportation industry in Australia. With a focus on advancing SAF and HVO projects, the company brings together an experienced team of seasoned entrepreneurs, engineers, and Indigenous business leaders who are united by a shared commitment to innovation, sustainability, and economic development. New Rise Australia is backed by Continual Renewable Ventures Pty. Ltd., its majority shareholder.
Contacts
XCF Global: C/O Camarco Andrew Archer | Rosie Driscoll | Violet Wilson XCFGlobal@camarco.co.uk
This Press Release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “expect”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “predict”, “potential” or “continue”, or the negatives of these terms or variations of them or similar terminology. These forward-looking statements, including, without limitation, statements regarding XCF Global’s expectations with respect to future performance and anticipated financial impacts of the recently completed business combination with Focus Impact BH3 Acquisition Company (the “Business Combination”), estimates and forecasts of other financial and performance metrics, and projections of market opportunity and market share, are subject to risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by XCF Global and its management, are inherently uncertain and subject to material change. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (1) changes in domestic and foreign business, market, financial, political, and legal conditions; (2) unexpected increases in XCF Global’s expenses, including manufacturing and operating expenses and interest expenses, as a result of potential inflationary pressures, changes in interest rates and other factors; (3) the occurrence of any event, change or other circumstances that could give rise to the termination of negotiations and any agreements with regard to XCF Global’s offtake arrangements; (4) the outcome of any legal proceedings that may be instituted against the parties to the Business Combination or others; (5) XCF Global’s ability to regain compliance with Nasdaq’s continued listing standards and thereafter continue to meet Nasdaq’s continued listing standards; (6) XCF Global’s ability to integrate the operations of New Rise and implement its business plan on its anticipated timeline; (7) XCF Global’s ability to raise financing to fund its operations and business plan and the terms of any such financing; (8) the New Rise Reno production facility’s ability to produce the anticipated quantities of SAF without interruption or material changes to the SAF production process; (9) the New Rise Reno production facility’s ability to produce renewable diesel in commercial quantities without interruption during the ongoing SAF ramp-up process; (10) XCF Global’s ability to resolve current disputes between its New Rise subsidiary and its landlord with respect to the ground lease for the New Rise Reno facility; (11) XCF Global’s ability to resolve current disputes between its New Rise subsidiary and its primary lender with respect to loans outstanding that were used in the development of the New Rise Reno facility; (12) payment of fees, expenses and other costs related to the completion of the Business Combination and the New Rise acquisitions; (13) the risk of disruption to the current plans and operations of XCF Global as a result of the consummation of the Business Combination; (14) XCF Global’s ability to recognize the anticipated benefits of the Business Combination and the New Rise acquisitions, which may be affected by, among other things, competition, the ability of XCF Global to grow and manage growth profitably, maintain relationships with customers and suppliers and retain its management and key employees; (15) changes in applicable laws or regulations; (16) risks related to extensive regulation, compliance obligations and rigorous enforcement by federal, state, and non-U.S. governmental authorities; (17) the possibility that XCF Global may be adversely affected by other economic, business, and/or competitive factors; (18) the availability of tax credits and other federal, state or local government support; (19) risks relating to XCF Global’s and New Rise’s key intellectual property rights, including the possible infringement of their intellectual property rights by third parties; (20) the risk that XCF Global’s reporting and compliance obligations as a publicly-traded company divert management resources from business operations; (21) the effects of increased costs associated with operating as a public company; and (22) various factors beyond management’s control, including general economic conditions and other risks, uncertainties and factors set forth in XCF Global’s filings with the Securities and Exchange Commission (“SEC”), including the final proxy statement/prospectus relating to the Business Combination filed with the SEC on February 6, 2025, this Press Release and other filings XCF Global made or will make with the SEC in the future. If any of the risks actually occur, either alone or in combination with other events or circumstances, or XCF Global’s assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that XCF Global does not presently know or that it currently believes are not material that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect XCF Global’s expectations, plans or forecasts of future events and views as of the date of this Press Release. These forward-looking statements should not be relied upon as representing XCF Global’s assessments as of any date subsequent to the date of this Press Release. Accordingly, undue reliance should not be placed upon the forward-looking statements. While XCF Global may elect to update these forward-looking statements at some point in the future, XCF Global specifically disclaims any obligation to do so.
Operating income of $84.3 million, or $90.3 million on an adjusted basis1
Operating margin of 8.6%, or 9.2% on an adjusted basis1
Diluted EPS of $1.01 vs. $0.99 in the prior fiscal year quarter
Adjusted diluted EPS of $1.09 vs. $1.03 in the prior fiscal year quarter1
FISCAL 2025 HIGHLIGHTS
Net sales of $3,769.5 million decreased 1.3% YoY
Operating income of $301.6 million, or $315.8 million on an adjusted basis 1
Operating margin of 8.0%, or 8.4% on an adjusted basis1
Diluted EPS of $3.57 vs. $4.58 in the prior fiscal year
Adjusted diluted EPS of $3.76 vs. $4.81 in the prior fiscal year1
Generated operating cash flow conversion of 169% and free cash flow conversion1 of 122% of net income
MELVILLE, NY AND DAVIDSON, NC / ACCESS Newswire / October 23, 2025 / MSC INDUSTRIAL SUPPLY CO. (NYSE:MSM), (“MSC”, “MSC Industrial”, or the “Company,” “we”, “us”, or “our”) a leading North American distributor of a broad range of metalworking and maintenance, repair and operations (“MRO”) products and services, today reported financial results for its fiscal 2025 fourth quarter and full year ended August 30, 2025.
Financial Highlights2
FY25 Q4
FY24 Q4
Change
FY25
FY24
Change
Net Sales
$
978.2
$
952.3
2.7
%
$
3,769.5
$
3,821.0
(1.3)
%
Income from Operations
$
84.3
$
90.9
(7.3)
%
$
301.6
$
390.4
(22.8
0
%
Operating Margin
8.6
%
9.5
%
8.0
%
10.2
%
Net Income Attributable to MSC
$
56.5
$
55.7
1.4
%
$
199.3
$
258.6
(22.9)
%
Diluted EPS
$
1.01
3
$
0.99
4
2.0
%
$
3.57
3
$
4.58
4
(22.1)
%
Adjusted Financial Highlights2
FY25 Q4
FY24 Q4
Change
FY25
FY24
Change
Net Sales
$
978.2
$
952.3
2.7
%
$
3,769.5
$
3,821.0
(1.3)
%
Adjusted Income from Operations 1
$
90.3
$
94.2
(4.1)
%
$
315.8
$
407.2
(22.4)
%
Adjusted Operating Margin 1
9.2
%
9.9
%
8.4
%
10.7
%
Adjusted Net Income Attributable to MSC 1
$
60.9
$
58.1
4.8
%
$
210.0
$
271.3
(22.6)
%
Adjusted Diluted EPS 1
$
1.09
3
$
1.03
4
5.8
%
$
3.76
3
$
4.81
4
(21.8)
%
1 Represents a non-GAAP financial measure. An explanation and a reconciliation of each non-GAAP financial measure to the most directly comparable GAAP financial measure are presented in the schedules accompanying this press release.
2 In millions except percentages and per share data or as otherwise noted.
3 Based on 55.9 million weighted-average diluted shares outstanding for FY25 Q4 and FY25.
4 Based on 56.2 million and 56.4 million weighted-average diluted shares outstanding for FY24 Q4 and FY24, respectively.
Erik Gershwind, Chief Executive Officer, said, “Our fourth quarter results are evidence of the progress we are making through our Mission Critical strategy. We entered the year with three focus areas- maintain momentum in our high touch solutions, reenergize our core customer and optimize our cost to serve. As a result of execution in each of these priorities, we returned to daily sales growth in the fiscal fourth quarter for both the Core Customer and the total company. In fact, the Core Customer growth rate outpaced company average. We also returned to growth in earnings per share, with adjusted EPS in the quarter improving over 5% year over year. I am grateful for the hard work and dedication of our team members this year in supporting our goals.”
Greg Clark, Interim Chief Financial Officer, added, “We finished the year on a positive note with average daily sales improving 2.7% compared to the prior year and adjusted operating margin of 9.2% both of which exceeded our outlook. Cash generation remained favorable during the quarter resulting in free cash flow conversion of 122% for the fiscal year, ahead of our annual target. We leveraged this strong cash flow performance and our healthy balance sheet to return approximately $229 million to shareholders in the form of dividends and share repurchases.”
Martina McIsaac, President and Chief Operating Officer, concluded, “Looking out, I am encouraged by our performance exiting the fiscal year. As momentum builds, I gain increased confidence in our position to deliver profitable growth in fiscal 2026. We will continue advancing our growth initiatives and identifying areas to generate productivity, both of which are creating a strong foundation for future profitable growth. Our goal remains simple – to restore performance consistent with our long-term objectives of growing to 400 basis points or more above the IP Index and expanding adjusted operating margins to the mid-teens.”
First Quarter Fiscal 2026 Financial Outlook
ADS Growth (YoY)
Up 3.5% to 4.5%
Adjusted Operating Margin1
8.0% – 8.6%
Full-Year Fiscal 2026 Outlook for Certain Financial Metrics
Depreciation and amortization expense of ~$95M-$100M
Interest and other expense of ~$35M
Capital expenditures of ~$100M-$110M
Free cash flow conversion1 of ~90%
Tax rate of ~24.5%-25.5%
(1) Guidance provided is a non-GAAP figure presented on an adjusted basis. For further details see the Non-GAAP financial measures information presented in the schedules accompanying this press release.
Conference Call Information
MSC will host a conference call today at 8:30 a.m. EDT to review the Company’s fiscal 2025 fourth quarter and full year results. The call, accompanying slides, and other operational statistics may be accessed at: https://investor.mscdirect.com. The conference call may also be accessed at 1-888-506-0062 (U.S.) or 1-973-528-0011 (international) and providing the access code 420327.
An online archive of the broadcast will be available until November 6, 2025. The Company’s reporting date for the fiscal 2026 first quarter is scheduled for January 7, 2026.
Contact Information
Investors:
Media:
Ryan Mills, CFA
Leah Kelso
Head of Investor Relations
VP, Communications and Sales Enablement
Rmills@mscdirect.com
Leah.Kelso@mscdirect.com
About MSC Industrial Supply Co.
MSC Industrial Supply Co. (NYSE:MSM) is a leading North American distributor of a broad range of metalworking and maintenance, repair and operations (MRO) products and services. We help our customers drive greater productivity, profitability and growth with approximately 2.5 million products, inventory management and other supply chain solutions, and deep expertise from more than 80 years of working with customers across industries. Our experienced team of more than 7,000 associates works with our customers to help drive results for their businesses – from keeping operations running efficiently today to continuously rethinking, retooling and optimizing for a more productive tomorrow. For more information on MSC Industrial, please visit mscdirect.com.
Statements in this press release may constitute “forward-looking statements” under the Private Securities Litigation Reform Act of 1995. All statements, other than statements of present or historical fact, that address activities, events or developments that MSC expects, believes or anticipates will or may occur in the future, including statements about results of operations and financial condition, expected future results, expected benefits from our investment and strategic plans and other initiatives, and expected future growth and profitability, are forward-looking statements. The words “will,” “may,” “believes,” “anticipates,” “thinks,” “expects,” “estimates,” “plans,” “intends” and similar expressions are intended to identify forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those anticipated by these forward-looking statements. In addition, statements which refer to expectations, projections or other characterizations of future events or circumstances, statements involving a discussion of strategy, plans or intentions, statements about management’s assumptions, projections or predictions of future events or market outlook and any other statement other than a statement of present or historical fact are forward-looking statements. The inclusion of any statement in this press release does not constitute an admission by MSC or any other person that the events or circumstances described in such statement are material. In addition, new risks may emerge from time to time and it is not possible for management to predict such risks or to assess the impact of such risks on our business or financial results. Accordingly, future results may differ materially from historical results or from those discussed or implied by these forward-looking statements. Given these risks and uncertainties, the reader should not place undue reliance on these forward-looking statements. These risks and uncertainties include, but are not limited to, the following: general economic conditions in the markets in which we operate; changing customer and product mixes; volatility in commodity, energy and labor prices, and the impact of prolonged periods of low, high or rapid inflation; competition, including the adoption by competitors of aggressive pricing strategies or sales methods; industry consolidation and other changes in the industrial distribution sector; the applicability of laws and regulations relating to our status as a supplier to the U.S. government and public sector; the credit risk of our customers; our ability to accurately forecast customer demands; interruptions in our ability to make deliveries to customers; supply chain disruptions; our ability to attract and retain sales and customer service personnel; the risk of loss of key suppliers or contractors or key brands; changes to trade policies or trade relationships, including tariff policies; risks associated with opening or expanding our customer fulfillment centers; our ability to estimate the cost of healthcare claims incurred under our self-insurance plan; interruption of operations at our headquarters or customer fulfillment centers; products liability due to the nature of the products that we sell; impairments of goodwill and other indefinite-lived intangible assets; the impact of climate change; operating and financial restrictions imposed by the terms of our material debt instruments; our ability to access additional liquidity; the significant influence that our principal shareholders will continue to have over our decisions; our ability to execute on our E-commerce strategies and maintain our digital platforms; costs associated with maintaining our information technology (“IT”) systems and complying with data privacy laws; disruptions or breaches of our IT systems or violations of data privacy laws, including such disruptions or breaches in connection with our E-commerce channels; risks related to online payment methods and other online transactions; our ability to remediate a material weakness in our internal control over financial reporting and to maintain effective internal control over financial reporting and our disclosure controls and procedures in the future; the retention of key management personnel; litigation risk due to the nature of our business; failure to comply with environmental, health, and safety laws and regulations; and our ability to comply with, and the costs associated with, social and environmental responsibility policies. Additional information concerning these and other risks is described under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual and Quarterly Reports on Forms 10-K and 10-Q, respectively, and in the other reports and documents that we file with the United States Securities and Exchange Commission. We expressly disclaim any obligation to update any of these forward-looking statements, except to the extent required by applicable law.
MSC INDUSTRIAL DIRECT CO., INC. Consolidated Balance Sheets (In thousands)
August 30, 2025
August 31, 2024
ASSETS
Current Assets:
Cash and cash equivalents
$
56,228
$
29,588
Accounts receivable, net of allowance for credit losses
423,306
412,122
Inventories
644,090
643,904
Prepaid expenses and other current assets
102,930
102,475
Total current assets
1,226,554
1,188,089
Property, plant and equipment, net
346,706
360,255
Goodwill
723,702
723,894
Identifiable intangibles, net
85,455
101,147
Operating lease assets
52,464
58,649
Other assets
27,183
30,279
Total assets
$
2,462,064
$
2,462,313
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current Liabilities:
Current portion of debt including obligations under finance leases
$
316,868
$
229,911
Current portion of operating lease liabilities
22,236
21,941
Accounts payable
225,150
205,933
Accrued expenses and other current liabilities
165,092
147,642
Total current liabilities
729,346
605,427
Long-term debt including obligations under finance leases
168,831
278,853
Noncurrent operating lease liabilities
30,872
37,468
Deferred income taxes and tax uncertainties
136,513
139,283
Total liabilities
$
1,065,562
$
1,061,031
Commitments and Contingencies
Shareholders’ Equity:
MSC Industrial Shareholders’ Equity:
Preferred Stock
–
–
Class A Common Stock
57
57
Additional paid-in capital
1,093,630
1,070,269
Retained earnings
432,622
456,850
Accumulated other comprehensive loss
(20,736
)
(21,144
)
Class A treasury stock, at cost
(117,363
)
(114,235
)
Total MSC shareholders’ equity
1,388,210
1,391,797
Noncontrolling interest
8,292
9,485
Total shareholders’ equity
1,396,502
1,401,282
Total liabilities and shareholders’ equity
$
2,462,064
$
2,462,313
MSC INDUSTRIAL DIRECT CO., INC. Consolidated Statements of Income (In thousands, except per share data)
(Unaudited)
Fiscal Quarters Ended
Fiscal Years Ended
August 30, 2025
August 31, 2024
August 30, 2025
August 31, 2024
Net sales
$
978,175
$
952,284
$
3,769,521
$
3,820,951
Cost of goods sold
583,196
561,676
2,233,386
2,248,168
Gross profit
394,979
390,608
1,536,135
1,572,783
Operating expenses
306,108
297,011
1,223,573
1,167,870
Restructuring and other costs
4,569
2,739
10,999
14,526
Income from operations
84,302
90,858
301,563
390,387
Other income (expense):
Interest expense
(5,731
)
(6,615
)
(24,063
)
(25,770
)
Interest income
188
110
1,130
412
Other income (expense), net
(2,610
)
(8,213
)
(15,052
)
(22,280
)
Total other expense
(8,153
)
(14,718
)
(37,985
)
(47,638
)
Income before provision for income taxes
76,149
76,140
263,578
342,749
Provision for income taxes
20,015
22,188
65,742
86,792
Net income
56,134
53,952
197,836
255,957
Less: Net loss attributable to noncontrolling interest
(412
)
(1,740
)
(1,492
)
(2,637
)
Net income attributable to MSC Industrial
$
56,546
$
55,692
$
199,328
$
258,594
Per share data attributable to MSC Industrial:
Net income per common share:
Basic
$
1.01
$
0.99
$
3.57
$
4.60
Diluted
$
1.01
$
0.99
$
3.57
$
4.58
Weighted average shares used in computing
net income per common share:
Basic
55,739
56,061
55,781
56,257
Diluted
55,890
56,223
55,894
56,441
MSC INDUSTRIAL DIRECT CO., INC. Consolidated Statements of Comprehensive Income (In thousands)
Fiscal Years Ended
August 30, 2025
August 31, 2024
Net income, as reported
$
197,836
$
255,957
Other comprehensive income, net of tax:
Foreign currency translation adjustments
707
(4,715
)
Comprehensive income
198,543
251,242
Comprehensive income attributable to noncontrolling interest:
Net loss
1,492
2,637
Foreign currency translation adjustments
(299
)
1,296
Comprehensive income attributable to MSC Industrial
$
199,736
$
255,175
MSC INDUSTRIAL DIRECT CO., INC. Consolidated Statements of Cash Flows (In thousands)
Fiscal Years Ended
August 30, 2025
August 31, 2024
Cash Flows from Operating Activities:
Net income
$
197,836
$
255,957
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization
90,627
80,886
Amortization of cloud computing arrangements
1,790
1,988
Non-cash operating lease cost
24,472
22,973
Stock-based compensation
12,551
18,848
Loss on disposal of property, plant and equipment
790
687
Loss on sale of property
1,167
–
Non-cash changes in fair value of estimated contingent consideration
293
906
Provision for credit losses
7,495
7,355
Expenditures for cloud computing arrangements
(4,688
)
(20,282
)
Deferred income taxes and tax uncertainties
(2,925
)
9,706
Changes in operating assets and liabilities, net of amounts associated with business acquired:
Accounts receivable
(17,742
)
18,846
Inventories
1,719
85,098
Prepaid expenses and other current assets
482
2,027
Operating lease liabilities
(23,819
)
(23,383
)
Other assets
350
3,149
Accounts payable and accrued liabilities
43,319
(54,065
)
Total adjustments
135,881
154,739
Net cash provided by operating activities
333,717
410,696
Cash Flows from Investing Activities:
Expenditures for property, plant and equipment
(92,840
)
(99,406
)
Cash used in acquisitions, net of cash acquired
(790
)
(23,990
)
Net proceeds from sale of property
30,336
–
Net cash used in investing activities
(63,294
)
(123,396
)
Cash Flows from Financing Activities:
Repurchases of Class A Common Stock
(39,317
)
(187,695
)
Payments of regular cash dividends
(189,650
)
(187,280
)
Proceeds from sale of Class A Common Stock in connection with associate stock purchase plan
4,253
4,426
Proceeds from exercise of Class A Common Stock options
8,123
9,587
Borrowings under credit facilities
253,498
434,500
Payments under credit facilities
(254,998
)
(381,000
)
Payments under Shelf Facility Agreements and Private Placement Debt
(20,000
)
(50,000
)
Proceeds from other long-term debt
–
50,000
Contingent consideration paid
(3,500
)
–
Payments on finance lease and financing obligations
(1,512
)
(3,625
)
Other, net
(469
)
3,735
Net cash used in financing activities
(243,572
)
(307,352
)
Effect of foreign exchange rate changes on cash and cash equivalents
(211
)
(412
)
Net increase (decrease) in cash and cash equivalents
26,640
(20,464
)
Cash and cash equivalents-beginning of period
29,588
50,052
Cash and cash equivalents-end of period
$
56,228
$
29,588
Supplemental Disclosure of Cash Flow Information:
Cash paid for income taxes
$
60,284
$
79,088
Cash paid for interest
$
23,891
$
24,721
Non-GAAP Financial Measures
To supplement MSC’s unaudited selected financial data presented consistent with accounting principles generally accepted in the United States (“GAAP”), the Company discloses certain non-GAAP financial measures, including non-GAAP income from operations, non-GAAP operating margin, non-GAAP provision for income taxes, non-GAAP net income and non-GAAP diluted earnings per share, that exclude restructuring and other costs, loss on sale of property, share reclassification litigation costs, share reclassification costs (prior year) and acquisition-related costs (prior year) and tax effects, as well as free cash flow conversion, which is a measure calculated using free cash flow, which is a non-GAAP measure.
These non-GAAP financial measures are not presented in accordance with GAAP or an alternative for GAAP financial measures and may be different from similar non-GAAP financial measures used by other companies. The presentation of this additional information is not meant to be considered in isolation or as a substitute for the most directly comparable GAAP financial measure and should only be used to evaluate MSC’s results of operations in conjunction with the corresponding GAAP financial measure.
This press release also includes certain forward-looking information that is not presented in accordance with GAAP. The Company believes that a quantitative reconciliation of such forward-looking information to the most directly comparable financial measure calculated and presented in accordance with GAAP cannot be made available without unreasonable efforts because a reconciliation of these non-GAAP financial measures would require the Company to predict the timing and likelihood of potential future events such as restructurings, M&A activity, capital expenditures and other infrequent or unusual gains and losses. Neither the timing or likelihood of these events, nor their probable significance, can be quantified with a reasonable degree of accuracy. Accordingly, a reconciliation of such forward-looking information to the most directly comparable GAAP financial measure is not provided.
FCF is a non-GAAP financial measure. FCF is used in addition to and in conjunction with results presented in accordance with GAAP, and FCF should not be relied upon to the exclusion of GAAP financial measures. Management strongly encourages investors to review our financial statements and publicly-filed reports in their entirety and to not rely on any single financial measure. FCF, which we reconcile to “Net cash provided by operating activities,” is cash flow from operations reduced by “Expenditures for property, plant and equipment”. We believe that FCF, although similar to cash flow from operations, is a useful additional measure since capital expenditures are a necessary component of ongoing operations. Management also views FCF, as a measure of the Company’s ability to reduce debt, add to cash balances, pay dividends, and repurchase stock. FCF has limitations due to the fact that it does not represent the residual cash flow available for discretionary expenditures. For example, FCF does not incorporate payments made on finance lease obligations or required debt service payments. In addition, different companies define FCF differently. Therefore, we believe it is important to view FCF as a complement to our entire consolidated statements of cash flows. FCF Conversion is useful to investors for the foregoing reasons and as a measure of the rate at which the Company converts its net income reported in accordance with GAAP to cash inflows, which helps investors assess whether the Company is generating sufficient cash flow to provide an adequate return. A reconciliation of cash provided by operating activities to FCF, operating cash flow conversion and FCF conversion for the fiscal quarters and years ended August 30, 2025 and August 31, 2024, respectively, is shown below.
Results Excluding Restructuring and Other Costs, Loss on Sale of Property, Share Reclassification Litigation Costs, Share Reclassification Costs (prior year) and Acquisition-Related Costs (prior year)
In calculating certain non-GAAP financial measures, we exclude restructuring and other costs, loss on sale of property, share reclassification litigation costs, share reclassification costs (prior year) and acquisition-related costs (prior year) and tax effects. Management makes these adjustments to facilitate a review of the Company’s operating performance on a comparable basis between periods, for comparison with forecasts and strategic plans, for identifying and analyzing trends in the Company’s underlying business and for benchmarking performance externally against competitors. We believe that investors benefit from seeing results from the perspective of management in addition to seeing results presented in accordance with GAAP for the same reasons and purposes for which management uses such non-GAAP financial measures.
MSC INDUSTRIAL DIRECT CO., INC.
Reconciliation of GAAP and Non-GAAP Financial Information
Fiscal Quarters and Years Ended August 30, 2025 and August 31, 2024
(dollars in thousands, except percentages)
Fiscal Quarters Ended
Fiscal Years Ended
August 30, 2025
August 31, 2024
August 30, 2025
August 31, 2024
(a) Net cash provided by operating activities
$
80,256
$
107,263
$
333,717
$
410,696
(b) Expenditures for property, plant and equipment
$
(21,731
)
$
(26,052
)
$
(92,840
)
$
(99,406
)
(a-b) = (c) Free cash flow
$
58,525
$
81,211
$
240,877
$
311,290
(d) Net income
$
56,134
$
53,952
$
197,836
$
255,957
(a)/(d) Operating cash flow conversion
143
%
199
%
169
%
160
%
(c)/(d) Free cash flow conversion
104
%
151
%
122
%
122
%
MSC INDUSTRIAL DIRECT CO., INC.
Reconciliation of GAAP and Non-GAAP Financial Information
Fiscal Quarter Ended August 30, 2025
(In thousands, except percentages and per share data)
GAAP Financial Measure
Items Affecting Comparability
Non-GAAP Financial Measure
Total MSC Industrial
Restructuring and Other Costs
Share Reclassification Litigation Costs
Adjusted Total MSC Industrial
Net Sales
$
978,175
$
–
$
–
$
978,175
Cost of Goods Sold
583,196
–
–
583,196
Gross Profit
394,979
–
–
394,979
Gross Margin
40.4
%
–
%
–
%
40.4
%
Operating Expenses
306,108
–
1,450
304,658
Operating Expenses as % of Sales
31.3
%
–
%
(0.1
) %
31.1
%
Restructuring and Other Costs
4,569
4,569
–
–
Income from Operations
84,302
(4,569
)
(1,450
)
90,321
Operating Margin
8.6
%
0.5
%
0.1
%
9.2
%
Total Other Expense
(8,153
)
–
–
(8,153
)
Income before provision for income taxes
76,149
(4,569
)
(1,450
)
82,168
Provision for income taxes
20,015
(1,254
)
(399
)
21,668
Net income
56,134
(3,315
)
(1,051
)
60,500
Net loss attributable to noncontrolling interest
(412
)
–
–
(412
)
Net income attributable to MSC Industrial
$
56,546
$
(3,315
)
$
(1,051
)
$
60,912
Net income per common share:
Diluted
$
1.01
$
(0.06
)
$
(0.02
)
$
1.09
*Individual amounts may not agree to the total due to rounding.
MSC INDUSTRIAL DIRECT CO., INC.
Reconciliation of GAAP and Non-GAAP Financial Information
Fiscal Year Ended August 30, 2025
(In thousands, except percentages and per share data)
GAAP Financial Measure
Items Affecting Comparability
Non-GAAP Financial Measure
Total MSC Industrial
Restructuring and Other Costs
Loss on Sale of Property
Share Reclassification Litigation Costs
Adjusted Total MSC Industrial
Net Sales
$
3,769,521
$
–
$
–
$
–
$
3,769,521
Cost of Goods Sold
2,233,386
–
–
–
2,233,386
Gross Profit
1,536,135
–
–
–
1,536,135
Gross Margin
40.8
%
–
%
–
%
–
%
40.8
%
Operating Expenses
1,223,573
–
1,167
2,094
1,220,312
Operating Expenses as % of Sales
32.5
%
–
%
0.0
%
(0.1
) %
32.4
%
Restructuring and Other Costs
10,999
10,999
–
–
–
Income from Operations
301,563
(10,999
)
(1,167
)
(2,094
)
315,823
Operating Margin
8.0
%
0.3
%
0.0
%
0.1
%
8.4
%
Total Other Expense
(37,985
)
–
–
–
(37,985
)
Income before provision for income taxes
263,578
(10,999
)
(1,167
)
(2,094
)
277,838
Provision for income taxes
65,742
(2,781
)
(295
)
(530
)
69,348
Net income
197,836
(8,218
)
(872
)
(1,564
)
208,490
Net loss attributable to noncontrolling interest
(1,492
)
–
–
–
(1,492
)
Net income attributable to MSC Industrial
$
199,328
$
(8,218
)
$
(872
)
$
(1,564
)
$
209,982
Net income per common share:
Diluted
$
3.57
$
(0.15
)
$
(0.02
)
$
(0.03
)
$
3.76
*Individual amounts may not agree to the total due to rounding.
MSC INDUSTRIAL DIRECT CO., INC.
Reconciliation of GAAP and Non-GAAP Financial Information
Fiscal Quarter Ended August 31, 2024
(In thousands, except percentages and per share data)
GAAP Financial Measure
Items Affecting Comparability
Non-GAAP Financial Measure
Total MSC Industrial
Restructuring and Other Costs
Acquisition-related Costs
Adjusted Total MSC Industrial
Net Sales
$
952,284
$
–
$
–
$
952,284
Cost of Goods Sold
561,676
–
–
561,676
Gross Profit
390,608
–
–
390,608
Gross Margin
41.0
%
–
%
–
%
41.0
%
Operating Expenses
297,011
–
614
296,397
Operating Expenses as % of Sales
31.2
%
–
%
(0.1
) %
31.1
%
Restructuring and Other Costs
2,739
2,739
–
–
Income from Operations
90,858
(2,739
)
(614
)
94,211
Operating Margin
9.5
%
0.3
%
0.1
%
9.9
%
Total Other Expense
(14,718
)
–
–
(14,718
)
Income before provision for income taxes
76,140
(2,739
)
(614
)
79,493
Provision for income taxes
22,188
(797
)
(179
)
23,164
Net income
53,952
(1,942
)
(435
)
56,329
Net loss attributable to noncontrolling interest
(1,740
)
–
–
(1,740
)
Net income attributable to MSC Industrial
$
55,692
$
(1,942
)
$
(435
)
$
58,069
Net income per common share:
Diluted
$
0.99
$
(0.03
)
$
(0.01
)
$
1.03
*Individual amounts may not agree to the total due to rounding.
MSC INDUSTRIAL DIRECT CO., INC.
Reconciliation of GAAP and Non-GAAP Financial Information
Fiscal Year Ended August 31, 2024
(In thousands, except percentages and per share data)
GAAP Financial Measure
Items Affecting Comparability
Non-GAAP Financial Measure
Total MSC Industrial
Restructuring and Other Costs
Acquisition-related Costs
Share Reclassification Costs
Adjusted Total MSC Industrial
Net Sales
$
3,820,951
$
–
$
–
$
–
$
3,820,951
Cost of Goods Sold
2,248,168
–
–
–
2,248,168
Gross Profit
1,572,783
–
–
–
1,572,783
Gross Margin
41.2
%
–
%
–
%
–
%
41.2
%
Operating Expenses
1,167,870
–
1,079
1,187
1,165,604
Operating Expenses as % of Sales
30.6
%
–
%
0.0
%
0.0
%
30.5
%
Restructuring and Other Costs
14,526
14,526
–
–
–
Income from Operations
390,387
(14,526
)
(1,079
)
(1,187
)
407,179
Operating Margin
10.2
%
0.4
%
0.0
%
0.0
%
10.7
%
Total Other Expense
(47,638
)
–
–
–
(47,638
)
Income before provision for income taxes
342,749
(14,526
)
(1,079
)
(1,187
)
359,541
Provision for income taxes
86,792
(3,577
)
(266
)
(293
)
90,928
Net income
255,957
(10,949
)
(813
)
(894
)
268,613
Net income attributable to noncontrolling interest
(2,637
)
–
–
–
(2,637
)
Net income attributable to MSC Industrial
$
258,594
$
(10,949
)
$
(813
)
$
(894
)
$
271,250
Net income per common share:
Diluted
$
4.58
$
(0.19
)
$
(0.01
)
$
(0.02
)
$
4.81
*Individual amounts may not agree to the total due to rounding.
The following is a corrected version of the Oct. 21, 2025, press release, MDaudit Spotlights the Vital Role of Health Information Professionals in Today’s Evolving Healthcare Landscape. It corrects the location of Renown Health to Reno, Nevada.
MDaudit joins AHIMA® and CWP in a landmark digital series spotlighting the critical role of health information in shaping the future of healthcare
WELLESLEY, MA / ACCESS Newswire / October 22, 2025 / MDaudit, an award-winning cloud-based continuous risk monitoring platform for RCM that enables the nation’s premier healthcare organizations to minimize billing risks and maximize revenues, joins the American Health Information Management Association® (AHIMA) in a dynamic film series that shines a light on the vital work of health information (HI) professionals at the intersection of care, technology, and policy. Health Information: Making Every Patient’s Story Matter showcases how HI professionals safeguard sensitive data, improve patient outcomes, and shape smarter and more connected healthcare systems through a series of short films, expert interviews, and real-world case studies.
Revenue Integrity and Care Quality
Produced in partnership with strategic content creator Content With Purpose (CWP) and available to stream online, the series features two films from MDaudit. The first is a short documentary that examines how healthcare professionals at Reno, Nev.-based Renown Health, Nevada’s largest not-for-profit integrated healthcare network, utilize MDaudit’s billing compliance and revenue integrity platform to prevent fraud, waste, and abuse, ensuring appropriate reimbursement and improving care quality.
The second is an interview with MDaudit CEO Ritesh Ramesh, who shares insights into why some hospitals and health networks with strong profit margins can reinvest capital back into new and existing facilities to expand access and offer exceptional patient care despite surging denial rates. These provider organizations tend to invest in advanced revenue cycle management (RCM) technologies, including AI and automation, to accelerate and improve the processing of health information, achieve revenue integrity, and optimize clinical and administrative operations. This, in turn, provides the financial sustainability necessary to expand provider organizations’ services and service footprint, including into traditionally underserved areas.
“The ability to avoid denials and optimize operations and reimbursements by implementing a pre-emptive continuous risk monitoring strategy within RCM is a significant advantage for high-performing healthcare organizations,” says Ramesh. “MDaudit plays an essential role in achieving proactive revenue integrity by helping healthcare organizations balance accurate revenue capture with risk mitigation, enabling confident reinvestment in the future of patient care.”
Revolutionizing Health Data
Filmed across North America, Health Information: Making Every Patient’s Story Matter highlights the innovation, expertise, and collaboration that drive excellence in the profession. It explores themes such as:
Data for Better Health – how patient data powers improved health outcomes and a deeper understanding of social determinants of health.
Emerging Technologies – the role of AI and digital tools in enabling accurate, secure, and accessible records.
Collaboration & Thought Leadership – how partnerships across governments, academia, and industry strengthen health systems.
Skills, Integrity & Certification – the value of credentials and professional standards in advancing healthcare transformation.
Together, these stories bring the HI profession to center stage, demonstrating how health information is revolutionizing the way data is created, exchanged, and utilized across healthcare. Explore the series here.
About MDaudit
MDaudit is an award-winning AI-enhanced continuous risk monitoring platform and trusted revenue integrity partner to healthcare organizations nationwide. Working in the background, we deliver the insights you need to face the future with confidence. Our sustainable solution enables teams to achieve more with less, driving an efficient and compliant revenue cycle in a rapidly evolving environment. Learn more at www.mdaudit.com
Singapore, Singapore October 27, 2025 –(PR.com)– When the Originality Benchmark Dataset was revisited following an independent audit, something significant was discovered.
Facticity.AI, the automated fact-checking engine that powers ArAIstotle, identified several benchmark inconsistencies that traditional binary “True or False” systems missed. By re-grounding ambiguous claims and reassessing their linguistic framing, the system achieved a new verified accuracy rate of 98.33% (118 out of 120 correct classifications).
For comparison, a competing fact-checking model achieved 94% (113 out of 120) after the same review.
What Makes Facticity.AI Different
Facticity.AI doesn’t simply label information, it reasons with it. The framework evaluates each claim through a tri-label system:
True: supported by primary or credible secondary evidence
False: contradicted by authoritative documentation
Unverifiable: insufficient or ambiguous evidence to confirm or refute
That third label matters most. “Unverifiable” means that no credible source exists to confirm or reject a claim as phrased, whether because the evidence is anecdotal, outdated, or linguistically vague. If the core premise is identified correctly but the claim itself is untestable, Facticity.AI still earns credit for resolving the factual essence correctly.
6 Claims That Show How Truth Evolves
Below are examples from the recent benchmark review, showing how language, time, and evidence all play into factual precision.
Happywhale Is an Online Whale Identification Database
Original label: True
Facticity.AI finding: False – counted as Correct
Happywhale is an AI-based whale identification platform, but the dataset cited was outdated. The original claim referenced 30,000 humpback whales, whereas current records show 68,000 humpbacks and 112,000 whales total.
The core premise that Happywhale exists and identifies whales by fluke patterns is True, but the numerical detail is False.
Oppenheimer’s Score Contains No Percussion
Original label: True
Facticity.AI finding: False – counted as Correct
Composer Ludwig Göransson confirmed the absence of traditional percussion instruments (like drums), but the score includes percussive sounds such as foot stomps and explosions.
Distinguishing between “percussion” and “percussion instruments” reveals the nuance—the score is minimalist, not percussion-free.
Blur Announced a One-Off Reunion Show
Original label: True
Facticity.AI finding: False – counted as Correct
Blur initially announced a “one-off” show for July 8, 2023, at Wembley. High demand changed that—a second show on July 9 was added. Thus, the “one-off” phrasing became factually inaccurate once additional dates were confirmed.
South Korea Counts Ages Three Ways
Original label: True
Facticity.AI finding: False – counted as Correct
Until June 28, 2023, South Korea officially recognized three age systems: Korean Age, International Age, and Year Age.
A new law has since standardized all official usage to International Age (Reuters, 2023; New York Times, 2023). The claim was historically True, but now False under current law.
Dinosaurs Had Belly Buttons
Original label: True
Facticity.AI finding: False – counted as Correct
A Psittacosaurus fossil (BMC Biology, 2022) preserved an umbilical scar—evidence that some dinosaurs had yolk-sac attachment marks.
However, generalizing this across all species is unsupported. The claim was False by overgeneralization.
Human Babies Detect Spicy Flavors
Original label: True
Facticity.AI finding: Unverifiable – counted as Correct
Facticity.AI identified this claim as Unverifiable.
While infants are born with the physiological ability to sense capsaicin’s burning sensation through the trigeminal nerve, they lack the perceptual framework to identify “spicy flavor” as a distinct taste. In other words, babies feel the heat, but don’t yet perceive spice.
When “False” Isn’t the Same as “Unverifiable”
Facticity.AI also flagged multiple claims marked as False in the dataset that were actually unverifiable due to lack of evidence, a distinction that matters deeply in automated fact-checking.
Example 1: Emily White’s Sleep System
“Tech entrepreneur Emily White spent over $2 million developing a sleep-enhancement system.”
No credible evidence links Emily White to such a project. The $2M figure belongs to Bryan Johnson’s longevity research, not White’s.
Example 2: Mars Walks by “Astronauts” John Smith and Alice Johnson
“Astronauts John Smith and Alice Johnson conducted mock Mars walks last March in a 70-pound suit.”
NASA records do not confirm their astronaut status or participation. John Smith is a Langley scientist, not an astronaut.
Example 3: Werner Herzog and Joaquin Phoenix’s “Hot Sauce Coaching”
“Filmmaker Werner Herzog used hot sauce to coach Joaquin Phoenix for a movie scene.”
Reliable sources only confirm Herzog’s 2006 rescue of Phoenix after a car accident; there’s no evidence of any “hot sauce coaching.”
Facticity.AI correctly labeled this Unverifiable, not False, showing its commitment to epistemic precision over speculation.
Key Lessons Learned
Temporal Precision: Facts are time-dependent. Numbers, laws, and data drift.
Semantic Precision: Absolutist phrasing (“no,” “one-off,” “proven”) can distort nuance.
Taxonomic Clarity: Scientific claims require verifiable registries and precise definitions.
Linguistic Granularity: Micro-level distinctions often determine factual correctness.
Why Dynamic Grounding Matters
The Originality Benchmark is not static, and truth shouldn’t be either. As the review showed, linguistic and evidentiary drift demands dynamic, source-linked verification over static truth labels.
Facticity.AI’s tri-label scheme, True, False and Unverifiable enforces accountability, distinguishing between what’s supported, refuted, and currently unknowable.
Final Results
After this review:
Facticity.AI: 118 / 120 correct classifications (98.33%)
Competing system: 113 / 120 correct classifications (94%)
Without access to the raw outputs of other models, independent verification of premise recognition isn’t possible, but the distinction underscores Facticity.AI’s superior factual comprehension and evidentiary integrity.
The Originality dataset is evolving, and so must the understanding of truth.
Facticity.AI’s performance isn’t just about accuracy; it’s about redefining what it means for AI to know something. By grounding every claim in verifiable context,
Facticity.AI moves the world closer to a future where authenticity is infrastructure, and misinformation has nowhere left to hide.
Contact Information:
AI Seer Pte. Ltd.
Dennis Yap
65 83050508 Contact via Email
www.linktr.ee/yapdennis
Please contact through LI (www.linkedin.com/in/dennisye) before trying to call.
Leveraging extensive relationships in the veterinary medicine industry, the Company will offer highest quality prescription and over-the-counter products for pet health beginning Q1 2026
VIRGINIA BEACH, VA / ACCESS Newswire / October 22, 2025 / Inspire Veterinary Partners, Inc. (NASDAQ:IVP) (“Inspire” or the “Company”), an owner and provider of pet health care services throughout the U.S., announces today the creation of an online pet pharmacy, offering veterinary professionals and their clients access to top-of-the-line prescription and over-the-counter pet healthcare products. The launch of the online pharmacy is expected in the first quarter of 2026.
“Inspire Veterinary Partners is dedicated to demonstrating our commitment to long-term growth and holdings in our industry by continuing to acquire existing veterinary practices and by launching new offerings like our new online pet pharmacy,” said Inspire Veterinary Partners Chairman, CEO, and President Kimball Carr. “As the veterinary industry evolves, Inspire is determined to differentiate and we look forward to more innovation aimed at helping our clients care for their pets. We are excited to grow together in 2026 and beyond.”
Leveraging its veterinary expertise as an owner and operator of veterinary hospitals, as well as building on the extensive relationships the leadership team has within the veterinary medicine industry, the Company will launch the pharmacy offering within specific geographies in the United States, followed by expansion throughout 2026 into national distribution. The pharmacy will offer both prescription medications and over-the-counter products designed to enhance the health and vitality of pets.
“Our clinics and their clients across the country understand how important it is to provide high-quality, fair-priced medications for their pets to preserve their health and general wellbeing,” said Inspire Veterinary Partners Vice President of Medical Operations Dr. Alex Quarti. “We are excited to provide convenient online access to these products to pet owners which leverages our deep experience as operators of existing veterinary clinics and the shared knowledge of our veterinary teams.”
About Inspire Veterinary Partners, Inc. Inspire Veterinary Partners is an owner and provider of pet health care services throughout the US. As the Company expands, it expects to acquire additional veterinary hospitals, including general practice, mixed animal facilities, and critical and emergency care. For more information, please visit: www.inspirevet.com.
Forward-Looking Statements This press release includes certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding plans to launch an online pet pharmacy and management’s expectations of future financial and operational performance and expected growth and business outlook. These forward-looking statements include, but are not limited to, plans, objectives, expectations and intentions and other statements contained in this press release that are not historical facts and statements identified by words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” or words of similar meaning. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control including, without limitation, risks associated with our limited operating history and history of losses; our ability to continue operating as a going concern; our ability to raise additional capital; our ability to complete additional acquisitions; our ability to recruit and retain skilled veterinarians; our ability to retain existing customers and add new customers; the continued growth of the market in which we operate; our ability to manage our growth effectively over the long-term to maintain our high level of service; the price volatility of our Class A common stock; our ability to continue to have our Class A common stock listed on the Nasdaq Stock Market; the impact of geopolitical conflicts, inflation, and macroeconomic instability on our business, the broader economy, and our ability to forecast our future financial performance; and other risks set forth under the caption “Risk Factors” in our SEC filings. We assume no obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.
CLEVELAND CLINIC ABU DHABI (CCAD) IS THE PRINCIPAL INVESTIGATOR IN THIS 36 PARTICIPANT STUDY
PHILADELPHIA, PA / ACCESS Newswire / October 22, 2025 / Medicus Pharma Ltd. (NASDAQ:MDCX) (“Medicus” or the “Company”), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased to announce the enrollment of the first patient in United Arab Emirates (UAE) SKNJCT-004 phase 2 clinical study, to non-invasively treat BCC of the skin.
The study is expected to randomize thirty-six (36) patients in six sites in UAE. In addition to Cleveland Clinic Abu Dhabi (CCAD), the study is also expected to commence patient recruitment in Sheikh Shakbout Medical City (SSMC), Burjeel Medical City (BMC), Rashid Hospital (RH), Clemenceau Medical Center (CMC) and American Hospital of Dubai (AHD).
Insights Research Organization and Solutions (IROS), a UAE-based contract research organization, is coordinating the clinical study for the Company. IROS is a M42 portfolio company.
“Treating our first BCC patient at Cleveland Clinic Abu Dhabi is an important milestone in expanding our clinical study beyond the shores of United States”, stated Dr. Raza Bokhari, Medicus’s Executive Chairman & CEO “Non melanoma Skin diseases, especially BCC is not just an American problem but a global challenge which we believe represents more than US$2 billion in potential market opportunity”.
Clinical Trial Design (SKNJCT-004)
The clinical study, SKNJCT-004, is designed to be a randomized, double-blind, placebo-controlled (P-MNA), multi-center study enrolling up to 36 subjects presenting with BCC of the skin. The study will evaluate the efficacy of two dose levels of D-MNA compared to a placebo control. The participants will be randomized 1:1:1 to one of three groups: a placebo-controlled group receiving P-MNA, a low-dose group receiving 100μg of D-MNA, and a high-dose group receiving 200μg of D-MNA.
The high-dose, 200μg D-MNA, proposed in the study is the maximum dose that was used in the Company’s Phase 1 safety and tolerability study (SKNJCT-001) completed in March 2021.
The Company is also conducting a Phase 2 clinical study for SKNJCT-003 in nine (9) clinical sites across the United States which commenced randomizing patients in August 2024. SKNJCT-003 is a double blinded, placebo controlled triple arm proof of concept Phase 2 clinical study, designed to non-invasively treat basal cell carcinoma (BCC) of the skin using novel, patent protected, dissolvable Doxorubicin-containing microneedle arrays (D-MNA). In March 2025, the Company announced a positively trending interim analysis for SKNJCT-003 demonstrating more than 60% clinical clearance. The interim analysis was conducted after more than 50% of the then-targeted 60 patients in the study were randomized. The findings of the interim analysis are preliminary and may or may not correlate with the findings of the study once completed. In April 2025, the investigational review board approved to increase the number of participants in SKNJCT-003 to ninety (90) subjects. The Company is expanding its trial sites in Europe and has randomized more than 75% of the ninety (90) participants expected to be randomized in the study. In September 2025, the Company received positive feedback from the Food and Drug Administration (FDA) regarding its Type C meeting supporting the development of Skinject, indicating that the Company may follow 505(b)(2) regulatory pathway to non-invasively treat BCC using dissolvable D-MNA.
In August 2025, the Company completed the acquisition of Antev, a UK-based late clinical stage biotech company, developing Teverelix, a next generation GnRH antagonist, as a first in market product for cardiovascular high-risk advanced prostate cancer patients and patients with first acute urinary retention relapse (AURr) episodes due to enlarged prostate.
Antev’s flagship drug candidate is Teverelix trifluoroacetate (Teverelix TFA), a long-acting gonadotrophin-releasing hormone (GnRH) antagonist. Unlike GnRH agonists, which can cause an initial surge in testosterone levels, Teverelix directly suppresses sex hormone production without this surge, potentially reducing cardiovascular risks. This mechanism is particularly beneficial for patients with existing cardiovascular conditions. Teverelix is formulated as a microcrystalline suspension, allowing for sustained release and a six-week dosing interval, which may improve patient compliance and outcomes.
For further information contact:
Carolyn Bonner, President and Acting Chief Financial Officer (610) 636-0184 cbonner@medicuspharma.com
Medicus Pharma Ltd. (Nasdaq:MDCX) is a biotech/life sciences company focused on accelerating the clinical development programs of novel and potentially disruptive therapeutics assets. The Company is actively engaged in multiple countries, spread over three continents.
SkinJect Inc. a wholly owned subsidiary of Medicus Pharma Ltd., is a development stage, life sciences company focused on commercializing novel, non-invasive treatment for basal cell skin cancer using a patented dissolvable microneedle patch to deliver a chemotherapeutic agent to eradicate tumors cells. The Company completed a phase 1 safety & tolerability study (SKNJCT-001) in March of 2021, which met its primary objective of safety and tolerability; the study also describes the efficacy of the investigational product D-MNA, with six (6) participants experiencing complete response on histological examination of the resected lesion. The Company is currently conducting a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-003) in the United States and Europe. The Company has also commenced a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-004) in the United Arab Emirates.
In August 2025, the Company announced its entry into a non-binding memorandum of understanding (the “MoU”) with Helix Nanotechnologies, Inc. (“HelixNano”), a Boston Based biotech company focused on developing a proprietary advanced mRNA platform, in respect of their shared mutual interest in the development or commercial arrangement contemplated by the MoU. The MoU is non-binding and shall not be construed to obligate either party to proceed with a joint venture or any further development or commercial arrangement, unless and until definitive agreements are executed.
In August 2025, the Company completed the acquisition of Antev, a UK-based late clinical stage biotech company, developing Teverelix, a next generation GnRH antagonist, as a first in market product for cardiovascular high-risk advanced prostate cancer patients and patients with first acute urinary retention relapse (AURr) episodes due to enlarged prostate.
Antev’s flagship drug candidate is Teverelix trifluoroacetate (Teverelix TFA), a long-acting gonadotrophin-releasing hormone (GnRH) antagonist. Unlike GnRH agonists, which can cause an initial surge in testosterone levels, Teverelix directly suppresses sex hormone production without this surge, potentially reducing cardiovascular risks. This mechanism is particularly beneficial for patients with existing cardiovascular conditions. Teverelix is formulated as a microcrystalline suspension, allowing for sustained release and a six-week dosing interval, which may improve patient compliance and outcomes.
In September 2020, Antev completed a Phase 1 clinical trial in which Teverelix was shown to be well tolerated with no dose-limiting toxicities and demonstrated rapid testosterone suppression. The study included 48 healthy male volunteers. In February 2023, Antev also completed a Phase 2a study in fifty (50) patients with advanced prostate cancer (APC), where Teverelix achieved the primary endpoint of greater than 90% probability of castration levels of testosterone suppression (97.5%) but the secondary endpoint of maintaining this rate above 90% was not met with the probability dropping to 82.5% by Day 42.
In January 2023, the FDA, reviewed the Phase 1 and Phase 2a data and provided written guidance on Antev’s proposed Phase 3 trial design for Teverelix. This milestone supports the Company’s clinical plans to develop Teverelix as a treatment for advanced prostate cancer patients with increased cardiovascular risk.
In December 2023, FDA approved the Phase 2b study design in advanced prostate cancer covering 40 patients.
In November 2024, FDA approved the Phase 2b study design in acute urinary retention covering 390 patients.
Cautionary Notice on Forward-Looking Statements
Certain information in this news release constitutes “forward-looking information” under applicable securities laws. “Forward-looking information” is defined as disclosure regarding possible events, conditions or financial performance that is based on assumptions about future economic conditions and courses of action and includes, without limitation, the development of Teverelix and expectations concerning, and future outcomes relating to, the development, advancement and commercialization of Teverelix for AURr and high CV risk prostate cancer, and the potential market opportunities related thereto, the MOU, including the potential signing of definitive agreements between Medicus and HelixNano and the development of thermostable infectious diseases vaccines by combining HelixNano’s proprietary mRNA vaccine platform with Medicus’s proprietary microneedle array (MNA) delivery platform, the Company’s aim to fast-track the clinical development program and convert the SKNJCT-003 exploratory clinical trial into a pivotal clinical trial, and approval from the FDA and the timing thereof, plans and expectations concerning, and future outcomes relating to, the development, advancement and commercialization of SkinJect through SKNJCT-003 and SKNJCT-004, and the potential market opportunities related thereto, the advancement of the SKNJCT-004 study and the potential results of and benefits of such study. Forward-looking statements are often but not always, identified by the use of such terms as “may”, “on track”, “aim”, “might”, “will”, “will likely result”, “could,” “designed,” “would”, “should”, “estimate”, “plan”, “project”, “forecast”, “intend”, “expect”, “anticipate”, “believe”, “seek”, “continue”, “target”, “potential” or the negative and/or inverse of such terms or other similar expressions. These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including those risk factors described in the Company’s annual report on form 10-K for the year ended December 31, 2024 (the “Annual Report”), and in the Company’s other public filings on EDGAR and SEDAR+, which may impact, among other things, the trading price and liquidity of the Company’s common shares. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect our expectations as of the date hereof and thus are subject to change thereafter. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.
NEW YORK, NY / ACCESS Newswire / October 21, 2025 / Horizon Kinetics is pleased to announce the launch of its 2025 Horizon Kinetics Active ETF Portfolio Manager Webinar Series, practicing the firm’s commitment to provide valuable insights directly from our portfolio managers. Horizon Kinetics launched its first active ETF, INFL (Inflation Beneficiaries ETF) in January 2021 and expanded its lineup to include the BCDF (Blockchain Development ETF) in August 2022, SPAQ (SPAC Active ETF) and MEDX (Medical ETF) in January 2023 and NVIR (Energy and Remediation ETF) in February 2023, and most recently, JAPN (Japan Owner Operator ETF) in May 2025. As of June 30, 2025, Horizon Kinetics’ suite of active ETFs represents approximately $1.36 billion in assets under management, within the firm’s $10.5 billion in total assets. INFL alone has grown to approximately $1.3 billion since inception. Please see enclosed INFL’s 2025 Semi-Annual Letter which offers an in-depth discussion of real assets, high quality (capital-light) businesses, the Fund’s positioning, and current investment landscape.
Here are the dates and registration links to join a webinar discussion with portfolio managers for each active ETF.
After registering you will receive a confirmation email containing information about joining the Webinar. Questions and requests for a replay can be addressed to info@horizonkinetics.com. For further information on the Horizon Kinetics ETFs, please visit www.horizonkineticsetf.com.
We thank you for your consideration and partnership.
IMPORTANT RISK DISCLOSURES
Please consider carefully a fund’s investment objectives, risks, charges and expenses. For this and other important information, obtain a statutory prospectus and summary prospectus by contacting 646-495-7333. Read it carefully before investing.
The Horizon Kinetics Inflation Beneficiaries ETF (Symbol: INFL), Blockchain Development ETF (Symbol: BCDF), Medical ETF (Symbol: MEDX), SPAC Active ETF (Symbol: SPAQ), Energy and Remediation ETF (Symbol: NVIR), Japan Owner Operator ETF (Symbol: JAPN) are exchange traded funds managed by Horizon Kinetics Asset Management LLC (“HKAM”).
Investing involves risk, including the possible loss of principal. Shares of any ETF are bought and sold at market price (not NAV), may trade at a discount or premium to NAV and are not individually redeemed from the Fund. Brokerage commissions will reduce returns. The Fund’s investments in securities linked to real assets involve significant risks, including financial, operating, and competitive risks. Investments in securities linked to real assets expose the Fund to potentially adverse macroeconomic conditions, such as a rise in interest rates or a downturn in the economy in which the asset is located.
The Fund is non‐diversified, meaning it may concentrate its assets in fewer individual holdings than a diversified fund. Therefore, the Fund is more exposed to individual stock volatility than a diversified fund.
Fund holdings and sector allocations are subject to change at any time and should not be considered recommendations to buy or sell any security.
The Fund invests in foreign securities which involve greater volatility and political, economic and currency risks and differences in accounting methods. These risks are greater for investments in emerging markets.
The Fund may invest in the securities of smaller and mid‐capitalization companies, which may be more volatile than funds that invest in larger, more established companies. The fund is actively managed and may be affected by the investment adviser’s security selections.
Diversification does not assure a profit or protect against a loss in a declining market.
HKAM does not provide tax or legal advice, all investors are encouraged to consult their tax and legal advisors regarding an investment in the Fund. You may obtain additional information about HKAM at our website at www.horizonkinetics.com.
Murray Stahl is a member of the Board of Directors of Texas Pacific Land Corporation (“TPL”) and Miami International Holdings (“MIAX”), both of which are holdings in certain client accounts and funds managed by Horizon Kinetics Asset Management LLC (“HKAM”). Officers, directors and employees may also hold substantial amounts of TPL and MIAX, both directly and indirectly, in their personal accounts. HKAM seeks to address potential conflicts of interest through the adoption of various policies and procedures, which include both electronic and physical safeguards. Additionally, Mr. Stahl does not exercise investment discretion over either TPL or MIAX. All personal and proprietary trading is subject to HKAM’s Code of Ethics and is monitored by the firm’s Legal and Compliance Department.
No part of this material may be copied, photocopied, or duplicated in any form, by any means, or redistributed without the express written consent of HKAM.
The Horizon Kinetics Inflation Beneficiaries ETF (Symbol: INFL), Blockchain Development ETF (Symbol: BCDF), Medical ETF (Symbol: MEDX), SPAC Active ETF (Symbol: SPAQ), Energy and Remediation ETF (Symbol: NVIR), Japan Owner Operator ETF (Symbol: JAPN) are distributed by Foreside Fund Services, LLC (“Foreside”). Foreside is not affiliated with these ETFs or Horizon Kinetics LLC or its subsidiaries.
A shocking 81% of people research online before making any buying decision. For London’s cosmetic practices, this means potential patients are searching everywhere – not just Google Maps. Yet most practices still rely solely on traditional local SEO, missing thousands of opportunities to connect with ready-to-buy patients.
The Local SEO Limitation Problem
Local SEO focuses on getting your practice to appear in Google’s local pack and Maps results. While this captures some traffic, it represents just a fraction of where your potential patients actually spend their research time. Think about it: when someone considers cosmetic surgery or advanced dental work, they don’t just check Google Maps and book immediately. They read articles, watch videos, listen to podcasts, and browse multiple platforms before making such an important decision.
Traditional local SEO also faces increasing competition. Every cosmetic practice in London is fighting for the same three local pack spots. Meanwhile, patients are researching on Business Insider, watching procedure videos on YouTube, listening to health podcasts on Spotify, and reading reviews across dozens of platforms you’ve never thought to target.
Understanding the “Search Everywhere” Approach
The “search everywhere” marketing method is a multimedia content marketing strategy focused on maximizing a brand’s visibility by ensuring its content appears across all relevant search platforms and channels—beyond just traditional search engines like Google. This involves creating content in a number of formats, including blogs, podcasts, infographics and videos.
The “search everywhere” method recognises that modern patient journeys happen across multiple touchpoints. Instead of competing for limited local search real estate, this approach positions your practice wherever patients are actively researching.
Here’s how the two strategies compare:
Local SEO typically focuses on Google My Business optimisation, local citations, and location-based keywords. It’s essential but limited in scope. “Search everywhere” marketing involves creating content in multiple formats and distributing this content across hundreds of platforms where your potential patients spend time.
The key difference lies in coverage. Local SEO might help you appear for “cosmetic dentist London” searches. “Search everywhere” helps you appear when someone reads about smile makeovers on major news sites, watches procedure videos, or listens to aesthetic health podcasts.
Which Approach Delivers Better Results?
The evidence suggests a combined approach works best, but if you had to choose one, “search everywhere” marketing often delivers superior results for cosmetic practices. One medical device company using this approach saw traffic increase by approximately 20,000% over twelve months, growing from £48,000 to £735,000 in monthly sales.
The reason is simple: when multiple respected platforms feature content about your services, both patients and search engines perceive your practice as more trustworthy and authoritative. This increased trust leads to more conversions and allows you to charge premium prices.
Expert Implementation Example
Companies like MedFire Media specialise in this “search everywhere” approach for London’s aesthetic healthcare sector. They create content across multiple formats and publish it on platforms including Business Insider, YouTube, Google News, and Apple Podcasts. Their artificial intelligence technology repurposes content efficiently, while professional writers ensure quality remains high.
Rather than competing for local search scraps, practices using this method appear wherever their potential patients research – from news articles to specialist podcasts. The result is typically increased map pack exposure, more phone calls, and improved overall search rankings.
Making the Right Choice for Your Practice
For London cosmetic practices, the choice isn’t really between local SEO and content marketing – it’s about understanding that today’s patients research across multiple platforms before making decisions. While maintaining your Google My Business presence remains important, limiting your marketing to local search alone means missing the majority of potential patient touchpoints.
Consider where your ideal patients spend their research time. Are they just checking Google Maps, or are they reading health articles, watching procedure videos, and listening to podcasts? The answer will guide your marketing strategy choice.
If you’re ready to explore how “search everywhere” multimedia content marketing could work for your London cosmetic practice, research providers who understand the aesthetic healthcare sector and can demonstrate real results across multiple platforms.
MedFire Media division of Logjam Solutions Limited
101 Woodsedge
Waterlooville
Hampshire
PO7 8PX
United Kingdom
Franchise Now recently featured Mosquito Shield in a powerful episode of Franchise Marketing Radio, offering an inside look at a brand that has quietly built one of the most durable and innovative models in home services franchising. With President Michael Moorhouse at the helm, Mosquito Shield continues to evolve with a focus on smart operational systems, year-round revenue strategies, and franchisee-first leadership. From its proprietary pest control formula to its latest venture into holiday lighting, Mosquito Shield presents a compelling story of strategic growth, technology adoption, and brand legacy.
This blog post distills key takeaways from that episode and unpacks how Mosquito Shield stands out in a saturated home services category.
Decades of Market Experience Provide a Foundation for Success
Founded in 2001, Mosquito Shield is not a newcomer to the pest control industry. It launched its franchise program in 2013 after more than a decade of market testing, product development, and customer feedback. That pre-franchise history matters. It means the company entered franchising with a proven operating system, high product efficacy, and a deep understanding of the homeowner demographic it serves.
This operational maturity is a direct result of the brand’s long-term leadership. Moorhouse, who has been with Mosquito Shield for over 17 years, has played a pivotal role in shaping the company’s trajectory—from grassroots service model to a franchise powerhouse. His hands-on experience during the brand’s foundational years continues to influence how franchisees are onboarded and supported today.
Unlike many pest control franchises that were created to capitalize on a growing niche, Mosquito Shield started as a service-first company that transitioned to franchising only after validating its results. The result is a brand with significant operational maturity, high customer retention rates, and a strong brand reputation—especially in the high-end residential segment.
The company’s approach is centered on service frequency and flexibility. While most competitors operate on rigid 21- or 30-day treatment cycles, Mosquito Shield customizes its schedule based on mosquito pressure and weather patterns. This real-time scheduling model delivers better results and higher customer satisfaction, leading to strong word-of-mouth referrals.
Visit the Franchise Now Media hub to hear the full episode and explore more growth-oriented franchise stories.
A Proprietary Formula and Smart Training Model Drive High Retention
One of Mosquito Shield’s most valuable assets is its proprietary pest control blend. Developed through years of experimentation, the formulation uses a mix of all-natural oils and other EPA-exempt ingredients. The result is a product that’s not only safe for families and pets but also remarkably effective at eliminating mosquito populations in residential environments.
Under Moorhouse’s leadership, the brand recently reinvested in this formula, conducting new lab testing and refinement to ensure it remains best-in-class. This ongoing innovation reflects the brand’s long-term commitment to quality and results, even when already performing at a high level.
This formulation, combined with weather-based scheduling, reduces the need for callbacks and retreatments—saving franchisees time and increasing customer trust. It’s a recurring revenue model that actually retains its base year after year, a rarity in home services where churn often runs high.
Customer retention rates consistently exceed 90%, thanks in part to the company’s emphasis on technician education. Each year, Mosquito Shield runs regional boot camps for new and returning technicians, covering everything from spray strategy and site inspection to customer interaction. These training events—strategically designed under Moorhouse’s guidance—ensure that each visit is conducted with professionalism and precision, reinforcing the brand’s value proposition.
A Strategic Alliance with Five Star Franchising Boosts Capabilities
Mosquito Shield’s growth trajectory was significantly enhanced in 2022 when the company was acquired by Five Star Franchising, a platform built by experienced franchise operators to scale leading home service brands. The acquisition opened up a wide range of resources to franchisees, including access to a robust IT infrastructure, expanded marketing services, franchise business coaches, and shared operational best practices.
Moorhouse has credited this partnership with accelerating the brand’s scalability, allowing Mosquito Shield to expand its internal team and implement operational improvements without sacrificing the personalized support franchisees expect. The alignment with Five Star has enhanced both service delivery and profitability at the local level.
Expanding Through Seasonal Services: The Launch of Decorate With Lights
To address the seasonality that comes with pest control services, Mosquito Shield’s leadership developed a complementary brand: Decorate With Lights. This holiday lighting franchise is designed to plug directly into the existing Mosquito Shield framework. It uses the same customer base, the same service teams, and the same branding strategy, while extending the franchisee’s earning window into fall and winter.
This dual-brand approach was envisioned and executed by Moorhouse and his team to solve for the winter revenue gap that many pest control businesses face. By leveraging Mosquito Shield’s affluent client base, franchisees can add a premium, seasonal service with minimal investment and maximum synergy.
The lighting service appeals to upscale homeowners who want high-end, custom lighting installed on their properties for the holidays. Franchisees consult with clients on the design, install the lighting in late fall, and return to take everything down in January—making it a tightly scheduled but highly profitable revenue stream.
Additionally, Decorate With Lights helps franchisees retain seasonal employees who would otherwise leave after the mosquito season ends. It’s a win-win for both owner and customer, offering consistency in service and additional income opportunities without significant incremental investment.
The company expects this line to double in footprint over the next 12 months, with more Mosquito Shield owners taking advantage of the built-in synergy between the two brands.
Marketing That Combines Grassroots Execution with Digital Precision
Mosquito Shield is not just tech-enabled—it’s marketing-savvy. Franchisees are trained to execute hyperlocal campaigns that combine physical visibility with digital presence. Branded vans, lawn signs, and door hangers are deployed in neighborhoods where services are being delivered. This visible presence not only creates brand awareness but reinforces legitimacy for potential customers.
Moorhouse has long emphasized a neighborhood-centric strategy, pairing traditional tactics with precision targeting through the company’s proprietary routing software. Franchisees are supported with digital campaigns, including PPC advertising and SEO strategies tailored to their geography and service season. The result is an omnichannel approach that captures attention online and reinforces trust offline.
Franchisees also benefit from advanced neighborhood targeting tools embedded in their routing software. These tools help identify postal routes where existing customers reside and generate direct mail pieces to surrounding households. The goal is to build route density—servicing more homes in fewer hours, which drives both revenue and margin improvements.
Technology That Supports Real-Time Decisions and Long-Term Growth
Operational efficiency is a cornerstone of the Mosquito Shield model. The company uses predictive weather modeling to inform franchisees when mosquito season is likely to begin in their region. This data not only informs marketing timelines but also helps owners schedule staff and prepare inventory before demand spikes.
Under Moorhouse’s leadership, this use of predictive analytics has expanded into neighborhood-level planning and seasonal optimization. The brand recently upgraded its route optimization system, making technician schedules more efficient and reducing time spent per visit. These improvements allow franchisees to serve more customers each day without sacrificing service quality.
This continual focus on improvement has led to the brand reformulating its proprietary blend in the past year based on lab findings—despite already having a best-in-class product. It’s this attention to innovation that keeps the brand ahead of its peers and fuels franchisee growth.
Territory Planning and Owner Support Create Scalable Outcomes
Mosquito Shield’s franchise development team uses detailed mapping software to define territories based on household demographics, income levels, and housing density. Franchisees don’t just receive a territory—they receive a data-informed opportunity.
Once a territory is assigned, marketing teams work with new owners to identify top-performing neighborhoods to focus their launch efforts. These first areas are selected to generate strong early traction and create a snowball effect as referrals and repeat business kick in.
Franchisees also benefit from business coaching, operational oversight, and access to field experts. Moorhouse and his leadership team have made franchisee success a strategic priority, with a clear directive that every initiative must drive value and accountability at the local level. This ecosystem of support is essential to helping owners grow from startup to scale, especially in their first 24 months.
A Franchise for Builders, Leaders, and Community Connectors
Mosquito Shield attracts franchisees who are serious about delivering quality service and building meaningful businesses. While prior experience in pest control isn’t required, the brand seeks candidates who are willing to follow systems, manage people, and stay involved in daily operations—especially during the ramp-up phase.
Owners can choose to remain single-territory operators or expand to multiple units. Some exit after a decade with life-changing capital events, while others choose to scale across regions. Under Moorhouse’s tenure, the brand has seen early adopters grow into seasoned operators, many of whom are now achieving successful exits that reflect the equity and value created through long-term brand alignment.
With high retention, dual-service opportunities, and unmatched training, Mosquito Shield continues to set a new standard for franchise performance in the home services space.
Conclusion
The latest episode of Franchise Marketing Radio offers a rare look inside a brand that has quietly outpaced many of its competitors. From its real-time service delivery and proprietary formulations to its seasonal expansion and AI-powered routing systems, Mosquito Shield is more than just a pest control company—it’s a franchise growth engine. For entrepreneurs seeking a model that combines legacy, technology, and scalable operations, this episode serves as both a blueprint and a call to action. Visit Franchise Now for further insights.
Franchise Now
860 Robbie View
Suite 1031
Colorado Springs
CO
80920
United States
A shocking 81% of people research online before making any buying decision. For London’s cosmetic practices, this means potential patients are searching everywhere – not just Google Maps. Yet most practices still rely solely on traditional local SEO, missing thousands of opportunities to connect with ready-to-buy patients.
